MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    The epigenetic association of Parkinson’s disease risk gene- GPNMB rs199347 with drinking

    YC. Chen, SL. Wu, YP. Liaw (Changhua, Taiwan)

    Objective: This paper examines the epigenetic association of rs199347 polymorphism variants of the GPNMB with drinking and DNA methylation changes. Background: Neuroinflammatory response induced by alcohol…
  • 2023 International Congress

    Does hyposmia induce apathy in early Parkinson’s disease? Lessons from structural brain connectivity

    A. Martinez-Nunez, H. Soltanian-Zadeh, K. Latack, N. Ghazi, A. Mahajan (Detroit, USA)

    Objective: To study changes in microstructural integrity of white matter tracts associated with apathy in patients with early Parkinson’s disease (PD) and hyposmia Background: Smells…
  • 2023 International Congress

    LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte‐derived macrophages and SH-SY5Y

    T. Usenko, K. Basharova, A. Bezrukova, A. Izyumchenko, M. Nikolaev, G. Baydakova, S. Pavlova, E. Grigorieva, S. Medvedev, E. Zakharova, S. Zakian, S. Pchelina (Gatchina, Russian Federation)

    Objective: To assess whether inhibition of the kinase activity of LRRK2 affects changes in enzyme activity of sphingolipid hydrolase in the culture of dopaminergic neurons…
  • 2023 International Congress

    Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies

    J. Boyd, H. Fernandez, W. Poewe, A. Fasano, N. Kovács, K. Chaudhuri, M. Simu, J. Aldred, L. Lopiano, S. Parashos, J. Parra, L. Bergmann, P. Kukreja, M. Shah, O. Ladhani, G. Melzi, C. Yan, A. Antonini (Burlington, USA)

    Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…
  • 2023 International Congress

    Hypoxia‑induced astrocyte activation and its protective effect on Parkinson’s disease

    M. Kim, S-H. Kim, HN. Choi, JY. Je, SP. Yun (Jinju, Republic of Korea)

    Objective: In this study, we aimed to investigate whether hypoxic conditions can activate cerebral astrocytes and explore their protective effects on α-synuclein pre-formed fibril (PFF)-treated…
  • 2023 International Congress

    Improving inpatient medication management in hospitalized Parkinson’s patients

    R. Schell, J. Stroh, F. Phibbs, A. Depp, C. Eastburn, A. Boudreaux (Not Hispanic/Latino/Latina/Latinx, USA)

    Objective: Develop a process for Parkinson's patients to provide individualized medication management to reduce length of stay,, mortality, 30-day readmissions, and increase patient satisfaction. Background:…
  • 2023 International Congress

    Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort

    M. Fabbri, S. Tessier, V. Rousseau, JC. Corvol, A. Sommet, F. Tubach, Y. de Rycke, N. Bertille, Y. Selvarasa, S. Carvalho, C. Brefel-Courbon, F. Ory-Magne, O. Rascol (Blagnac, France)

    Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…
  • 2023 International Congress

    The effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial

    M. Salari, N. Valian, L. Mohaghegh Shalmani, R. Rashedi, H. Ashourizadeh, L. Dargahi (Tehran, Islamic Republic of Iran)

    Objective: To evaluating the effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial Background:…
  • 2023 International Congress

    Longitudinal change in clinical characteristics of LRRK2 carriers in a remote cohort

    S. Lettenberger, P. Auinger, R. Wilson, E. Hartman, M. Pawlik, M. Khokhar, E. Dorsey, B. Valdovinos, S. Sharma, R. Holloway, C. Tanner, R. Alcalay, R. Schneider (Rochester, USA)

    Objective: To examine change in clinical characteristics in LRRK2 G2019S carriers with Parkinson’s disease (PD) and without PD (non-manifest carriers) enrolled in Virtual Assessment of…
  • 2023 International Congress

    Longitudinal brain volume decline in PD with RBD and olfactory dysfunction

    K. Kawabata, E. Bagarinao, K. Seppi, W. Poewe (Innsbruck, Austria)

    Objective: To elucidate longitudinal brain atrophies in PD with or without RBD and anosmia at baseline. Background: REM sleep behavior disorder (RBD) and olfactory dysfunction…
  • « Previous Page
  • 1
  • …
  • 240
  • 241
  • 242
  • 243
  • 244
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley